EGFR and non-small cell lung carcinoma: EGFR is frequently and strongly expressed in HNSCCs [9], has prognostic and predictive value [17], and serves as an anchor for Food and Drug Administration (FDA)-approved therapeutic antibodies and inhibitors targeting EGFR, including monoclonal antibody Cetuximab, which is primarily implemented into palliative treatment of metastatic head and neck, colon, and non-small-cell lung cancer patients [18–20].